--- Page 0 ---
179U.S. Patent and Trademark Office, Commerce § 1.705 filed and ending on the date that the reply or other paper correcting the omission was filed; (8) Submission of a supplemental reply or other paper, other than a sup-plemental reply or other paper ex-pressly requested by the examiner, after a reply has been filed, in which case the period of adjustment set forth in §1.703 shall be reduced by the num-ber of days, if any, beginning on the day after the date the initial reply was filed and ending on the date that the supplemental reply or other such paper was filed; (9) Submission of an amendment or other paper after a decision by the Board of Patent Appeals and Inter-ferences, other than a decision des-ignated as containing a new ground of rejection under §1.196(b) or statement under §1.196(c), or a decision by a Fed-eral court, less than one month before the mailing of an Office action under 35 U.S.C. 132 or notice of allowance under 35 U.S.C. 151 that requires the mailing of a supplemental Office action or sup-plemental notice of allowance, in which case the period of adjustment set forth in §1.703 shall be reduced by the lesser of: (i) The number of days, if any, begin- ning on the day after the mailing date of the original Office action or notice of allowance and ending on the mailing date of the supplemental Office action or notice of allowance; or (ii) Four months; (10) Submission of an amendment under §1.312 or other paper after a no-tice of allowance has been given or mailed, in which case the period of ad-justment set forth in §1.703 shall be re-duced by the lesser of: (i) The number of days, if any, begin- ning on the date the amendment under §1.312 or other paper was filed and end-ing on the mailing date of the Office action or notice in response to the amendment under §1.312 or such other paper; or (ii) Four months; and (11) Further prosecution via a con- tinuing application, in which case the period of adjustment set forth in §1.703 shall not include any period that is prior to the actual filing date of the ap-plication that resulted in the patent. (d) A paper containing only an infor- mation disclosure statement in compli-ance with §§1.97 and 1.98 will not be considered a failure to engage in rea-sonable efforts to conclude prosecution (processing or examination) of the ap-plication under paragraphs (c)(6), (c)(8), (c)(9), or (c)(10) of this section if it is accompanied by a statement that each item of information contained in the information disclosure statement was cited in a communication from a for-eign patent office in a counterpart ap-plication and that this communication was not received by any individual des-ignated in §1.56(c) more than thirty days prior to the filing of the informa-tion disclosure statement. This thirty-day period is not extendable. (e) Submission of an application for patent term adjustment under §1.705(b) (with or without request under §1.705(c) for reinstatement of reduced patent term adjustment) will not be consid-ered a failure to engage in reasonable efforts to conclude prosecution (proc-essing or examination) of the applica-tion under paragraph (c)(10) of this sec-tion. [65 FR 56393, Sept. 18, 2000] § 1.705 Patent term adjustment deter- mination. (a) The notice of allowance will in- clude notification of any patent term adjustment under 35 U.S.C. 154(b). (b) Any request for reconsideration of the patent term adjustment indicated in the notice of allowance, except as provided in paragraph (d) of this sec-tion, and any request for reinstatement of all or part of the term reduced pur-suant to §1.704(b) must be by way of an application for patent term adjust-ment. An application for patent term adjustment under this section must be filed no later than the payment of the issue fee but may not be filed earlier than the date of mailing of the notice of allowance. An application for patent term adjustment under this section must be accompanied by: (1) The fee set forth in §1.18(e); and (2) A statement of the facts involved, specifying: (i) The correct patent term adjust- ment and the basis or bases under §1.702 for the adjustment; VerDate Dec<13>2002 11:53 Feb 03, 2003 Jkt 197133 PO 00000 Frm 00179 Fmt 8010 Sfmt 8010 Y:\SGML\197133T.XXX 197133T

--- Page 1 ---
18037 CFR Ch. I (7–1–02 Edition) § 1.710 (ii) The relevant dates as specified in §§1.703(a) through (e) for which an ad-justment is sought and the adjustment as specified in §1.703(f) to which the patent is entitled; (iii) Whether the patent is subject to a terminal disclaimer and any expira-tion date specified in the terminal dis-claimer; and (iv)(A) Any circumstances during the prosecution of the application result-ing in the patent that constitute a fail-ure to engage in reasonable efforts to conclude processing or examination of such application as set forth in §1.704; or (B) That there were no circumstances constituting a failure to engage in rea-sonable efforts to conclude processing or examination of such application as set forth in §1.704. (c) Any application for patent term adjustment under this section that re-quests reinstatement of all or part of the period of adjustment reduced pur-suant to §1.704(b) for failing to reply to a rejection, objection, argument, or other request within three months of the date of mailing of the Office com-munication notifying the applicant of the rejection, objection, argument, or other request must also be accom-panied by: (1) The fee set forth in §1.18(f); and (2) A showing to the satisfaction of the Commissioner that, in spite of all due care, the applicant was unable to reply to the rejection, objection, argu-ment, or other request within three months of the date of mailing of the Office communication notifying the ap-plicant of the rejection, objection, ar-gument, or other request. The Office shall not grant any request for rein-statement for more than three addi-tional months for each reply beyond three months from the date of mailing of the Office communication notifying the applicant of the rejection, objec-tion, argument, or other request. (d) If the patent is issued on a date other than the projected date of issue and this change necessitates a revision of the patent term adjustment indi-cated in the notice of allowance, the patent will indicate the revised patent term adjustment. If the patent indi-cates a revised patent term adjustment due to the patent being issued on a date other than the projected date of issue, any request for reconsideration of the patent term adjustment indi-cated in the patent must be filed with-in thirty days of the date the patent issued and must comply with the re-quirements of paragraphs (b)(1) and (b)(2) of this section. (e) The periods set forth in this sec- tion are not extendable. (f) No submission or petition on be- half of a third party concerning patent term adjustment under 35 U.S.C. 154(b) will be considered by the Office. Any such submission or petition will be re-turned to the third party, or otherwise disposed of, at the convenience of the Office. [65 FR 56394, Sept. 18, 2000] EXTENSION OF PATENT TERMDUE TO REGULATORY REVIEW § 1.710 Patents subject to extension of the patent term. (a) A patent is eligible for extension of the patent term if the patent claims a product as defined in paragraph (b) of this section, either alone or in com-bination with other ingredients that read on a composition that received permission for commercial marketing or use, or a method of using such a product, or a method of manufacturing such a product, and meets all other conditions and requirements of this subpart. (b) The term product referred to in paragraph (a) of this section means— (1) The active ingredient of a new human drug, antibiotic drug, or human biological product (as those terms are used in the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act) including any salt or ester of the active ingredient, as a single en-tity or in combination with another ac-tive ingredient; or (2) The active ingredient of a new animal drug or veterinary biological product (as those terms are used in the Federal Food, Drug, and Cosmetic Act and the Virus-Serum-Toxin Act) that is not primarily manufactured using re-combinant DNA, recombinant RNA, hybridoma technology, or other proc-esses including site specific genetic manipulation techniques, including VerDate Dec<13>2002 11:53 Feb 03, 2003 Jkt 197133 PO 00000 Frm 00180 Fmt 8010 Sfmt 8010 Y:\SGML\197133T.XXX 197133T